Senores Pharmaceuticals has reported a strong start to FY27, driven by broad-based growth across key business segments, improved profitability and continued expansion of its product portfolio.

 

The pharma powerhouse has posted consolidated revenue of Rs. 180.2 crore in Q1 FY27, marking a 35.9% year-on-year growth compared with Rs. 132.6 crore in Q1 FY26.

 

The company’s Regulated Markets business delivered a robust performance, with revenue rising 41.9% YoY to Rs. 127.8 crore, while Emerging Markets revenue grew 29.6% YoY to Rs. 37.6 crore. The Others segment also recorded healthy growth of 29.2% YoY, reaching Rs. 6.8 crore.

 

Branded Generics revenue stood at Rs. 8 crore during the quarter.

 

Senores reported a significant improvement in profitability during Q1 FY27, with EBITDA rising 87% YoY to Rs. 54 crore. EBITDA margin expanded by approximately 800 basis points year-on-year, reflecting the company’s continued focus on manufacturing efficiencies, operational excellence and cost optimisation.

 

Profit after tax (PAT) increased 56% YoY to Rs. 31 crore, highlighting strong earnings growth and improved financial performance.

 

The company continued to strengthen its regulated markets presence by significantly expanding its product pipeline.

 

Senores’ approved ANDA portfolio nearly doubled from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026, with 23 ANDAs already commercialised.

 

The expansion reflects the company’s strategy of combining in-house product development with targeted acquisitions to build a differentiated portfolio of complex and niche pharmaceutical products.

 

Senores’ Emerging Markets business continued its steady growth trajectory, recording approximately 30% YoY revenue growth in Q1 FY27.

 

The segment achieved an EBITDA margin of approximately 14%, supported by increasing focus on niche products and streamlined go-to-market strategies. The business has also turned cash flow positive, strengthening its long-term growth potential.

 

Commenting on the performance, Swapnil Shah, Managing Director, Senores Pharma, said, “Building on the strong momentum from the previous year and driven by our well-defined strategic priorities, we delivered a healthy performance in the first quarter of FY27 despite a challenging operating environment.

 

"Our Regulated Markets business delivered strong performance in Q1FY27, registering a robust 42% year-over-year revenue growth. This was driven by the continuous expansion of our product portfolio and differentiated sales & distribution channels. Through a balanced blend of in-house development and targeted acquisitions, we have strategically strengthened our ANDA portfolio."

 

He added: "The Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now near mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive.

 

"The addition of Baroda-based USFDA approved manufacturing plant enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO & CMO opportunities, positioning Senores for sustained growth. Production is already ramped up at Apnar facility, with full scale-up and further expansion is expected over the next 12–18 months.

 

"Our specific purpose marketing and distribution subsidiaries are expected to scale up significantly over the next few years and will structurally advance our entire U.S. business to multifold."